Category Archives: NIH

  1. Early HIV Treatment Helps Immune Function

    from The Times of India A new study has found that HIV-infected individuals who begin antiretroviral theraphy (ART) soon after acquiring the virus may have stronger immune responses to other pathogens than HIV-infected individuals who beging ART later. The findings from the National Institutes of Health (NIH) suggest that early initiation of ART may prevent irreversible immune Read More >>

    ARV, HIV/AIDS, NIH, research, Treatment
  2. NIH Releases Biennial Report of the Director

    via NIH News Media Branch Dr. Francis S. Collins, M.D., Ph.D, director of the National Institutes of Health, announced the release of the Biennial Report of the Director, NIH, for fiscal years 2008 and 2009. The report provides an integrated portrait of NIH research activities, making it easy for Congress, advocates and patient groups and the general Read More >>

    biomedical, NIH, research
  3. Join IRMA in learning the basic science of drug discovery

    via IRMA Enhance your advocacy skills and bone up on some of the basics. Dr. Jim Turpin of the Microbicide Research Branch at the National Institutes of Health, National Institutes of Allergy and Infectious Diseases, will explain the basic science of drug discovery – the research that happens before we move on to Phase I safety testing Read More >>

    Dr. Jim Turpin, IRMA, NIH, teleconference
  4. Dieffenbach – Future Priorities for NIAID’s HIV Prevention Research

    via, by Carl W. Dieffenbach, Ph.D., Director of NIAID’s Division of AIDS [Check out his June 9, 2010 presentation: Restructuring the HIV/AIDS Clinical Trials Networks] As we begin to discuss the restructuring of NIAID’s clinical trials networks, let us first focus on the Institute’s HIV prevention research agenda. Developing new biomedical tools that can safely and Read More >>

    HIV transmission, HIV/AIDS policy, new prevention technologies, NIH, PrEP, prevention, rectal microbicide, research, TLC+, Treatment, vaginal microbicide
  5. A Sound Investment:The Multiplier Effect of AIDS Research

    Check out the new issue brief from amfAR, The Foundation for AIDS Research, and Treatment Action Group (TAG) on the need to increase investment in AIDS and health research in FY11 and beyond. IRMA members will find that this is an excellent advocacy tool. The brief includes information on: – Inflation adjusted AIDS research and NIH funding Read More >>

    amfAR, behavioral research, funding, NIH, research, TAG
  6. $17 million grant to help Pitt researcher develop anti-HIV gel

    via Pittsburgh Post-Gazette, by David Templeton Highlight: Dr. McGowan said the size of the NIH grants reflects a change in Washington, D.C., where the Obama administration has shown greater interest in funding HIV-prevention research. “The Bush administration had a very high level of discomfort embracing HIV prevention research in men,” he said. “But I think in the Read More >>

    behavioral research, CHARM, Dr. Alex Carballo-Dieguez, Dr. Ian McGowan, MTN, NIH, Pittsburgh, rectal microbicide
  7. Pitt Receives Grants Totaling $17.5 million for Two HIV Prevention Projects: Multicenter Studies Will Develop Rectal Microbicides and Assess Their Acceptance

    via Erie Gay News A multicenter research team led by the University of Pittsburgh is developing microbicides specifically designed to prevent rectal transmission of HIV, with the further aim of assessing their safety and efficacy in lab and early clinical studies. Funded by an $11 million, five-year grant from the National Institutes of Health, the Combination HIV Read More >>

    CHARM, Dr. Ian McGowan, NIH, Pittsburgh, rectal microbicide, vaginal microbicide
  8. World AIDS Day and Rectal Microbicides in the Media

    Rectal microbicides were mentioned several times in the news yesterday in conjunction with World AIDS Day. Here are a couple of  items that caught our eye – a rectal sampler as it were. Statement from the National Institutes of Health on World AIDS Day 2009  Excerpt: The National Institute of Allergy and Infectious Diseases (NIAID) accounts for Read More >>

    advocacy, new prevention technologies, NIH, PrEP, rectal microbicide, vaccine
  9. Magee-Womens Research Institute Receives $17.5 million for Rectal Microbicide Research

    Dr. Ian McGowan* (pictured), an investigator with the Magee-Womens Research Institute (MWRI), recently received a total of $17.5 million from the National Institutes of Health (NIH) to conduct two studies involving the development of rectal microbicides. “This is exciting for the field of HIV prevention research, and especially important in terms of moving the research and development Read More >>

    acceptability, CHARM, Dr. Alex Carballo-Dieguez, Dr. Ian McGowan, IRMA, MTN, new prevention technologies, NIH, rectal microbicide
  10. NEW Rectal Microbicide Trial is Recruiting

    Official Title: “A Two-site, Phase 1, Partially-blinded, Placebo-controlled Safety, Acceptability and Pharmacokinetic Trial of Topical, Vaginally-formulated Tenofovir 1% Gel Applied Rectally Compared With Oral 300 mg Tenofovir Disoproxil Fumarate in HIV-1 Seronegative Adults” Clinical Trial Phase: Phase 1 | Start Date: September 2009 Overall Status: Recruiting Estimated Enrollment: 18 To date, the majority of microbicide research has Read More >>

    anal sex, CONRAD, Dr. Peter Anton, gay men, MSM, new prevention technologies, NIH, rectal microbicide, research, Tenofovir, women